Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Business Wire
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year ---- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 ---- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations ---- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 ---- Current Cash Expected to Fund Company into Mid-2027 ---- Conference Call Today at 8:30am ET – BOSTON, Mass.--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate a favorable safety and
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Astria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsBusiness Wire
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.MarketBeat
ATXS
Earnings
- 11/13/23 - Miss
ATXS
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- ATXS's page on the SEC website